NCT04658134

Glycine "Deficiency" and the Kinetics of Acylglycine in Morbid Obesity

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Singapore General Hospital · Academic / Other
• Sex: All
• Age: 21 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the effects of oral glycine supplementation on plasma glycine concentration, intracellular glutathione (GSH) concentration, plasma acylglycine concentration, urine acylglycine concentration, and insulin resistance in subjects with morbid obesity. This is an open-labelled trial. 20 adults with morbid obesity will be recruited. Following screening and baseline metabolic evaluations, eligible subjects will be given oral glycine supplements for 14 ± 5 days. Upon completing glycine supplementation, subjects will return for their post-supplement metabolic assessment. The investigators hypothesize that oral glycine supplementation in morbidly obese patients normalizes plasma glycine concentration, increases intracellular GSH concentration, increases plasma and urinary acylglycine concentration, and improves insulin resistance.

Conditions

• Morbid Obesity
• Glycine; Metabolic Disorder

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Glycine	Oral glycine tablets (100 mg/kg/day) in divided doses

Timeline

• Start date: 2021-01-20
• Primary completion: 2021-12-15
• Completion: 2021-12-15
• First posted: 2020-12-08
• Last updated: 2021-03-17

Locations

1 site across 1 country: Singapore